Sevuparin for the treatment of acute pain crisis in patients with sickle cell disease: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial-Reference-Cited by-同舟云学术

Sevuparin for the treatment of acute pain crisis in patients with sickle cell disease: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

Published:2021-05 Issue:5 Volume:8 Page:e334-e343
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Biemond Bart J,Tombak Anil,Kilinc Yurdanur,Al-Khabori Murtadha,Abboud Miguel,Nafea Mohammed,Inati Adlette,Wali Yasser,Kristensen Jens,Kowalski Jan,Donnelly Ellen,Ohd John,Nur Erfan,Rijneveld Anita W.,Antmen Alibülent,Reid Marvin,Ukala Gabriel,Kirven-Dawes Lisa,Yeates Curis,Wong Hugh,Al Sultan Abdulrahman

Publisher

Elsevier BV

Subject

Hematology

Reference27 articles.

1. Sickle cell disease;Ware;Lancet,2017

2. Sickle cell disease: clinical presentation and management of a global health challenge;Houwing;Blood Rev,2019

3. Sickle cell disease related mortality in the United States (1999–2009);Hamideh;Pediatr Blood Cancer,2013

4. Survival in adults with sickle cell disease in a high-income setting;Gardner;Blood,2016

5. Acute care utilization and rehospitalizations for sickle cell disease;Brousseau;JAMA,2010

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the genetic mechanisms: SELP gene’s contribution to alleviating vaso-occlusive crisis in sickle cell disease;Gene;2024-11

2. SEVUparin as a potential Adjunctive Treatment in children with severe malaria: A phase I trial safety and dose finding trial (SEVUSMAART);Wellcome Open Research;2024-08-12

3. A critical review of therapeutic interventions in sickle cell disease: Progress and challenges;Archiv der Pharmazie;2024-07-19

4. Selectins in Biology and Human Disease: Opportunity in E-selectin Antagonism;Cureus;2024-06-09

5. Successes and pitfalls in orphan drug development for sickle cell disease;Blood Advances;2024-05-20